- Biosapien has announced the expansion of its Pre-Series A funding round to $7 million to support the development of its groundbreaking MediChip platform.
- The company plans to launch clinical trials in the UAE by Q2 2025, focusing on treatments for colorectal cancer.
- MediChip leverages 3D printing technology to revolutionize drug delivery by providing targeted, slow-release medication. The technology aims to treat over 1 million patients by 2035, offering innovative solutions that enhance treatment efficiency and minimize side effects.
Dubai, UAE – Biosapien, a leading biotech company, has announced the expansion of its Pre-Series A funding round to $7 million. This milestone was achieved with the participation of new investors, including Golden Gate Ventures, marking its first investment in the Middle East and North Africa (MENA) region.
This funding builds on a previous $5.5 million round announced last December, led by Global Ventures with the participation of Dara Holdings.
Driving Innovation with the MediChip Platform
MediChip is a groundbreaking drug delivery system developed using 3D printing technology. It features slow drug-release capabilities and can be directly attached to affected tissues, reducing the required dosage while enhancing treatment efficacy and minimizing side effects.
Key Advantages of MediChip Technology:
- Direct Tumor Targeting: Focuses treatment on the tumor site.
- Reduced Drug Quantities: Minimizes medication usage.
- Fewer Systemic Side Effects: Enhances patient comfort and outcomes.
Biosapien plans to launch clinical trials targeting colorectal cancer patients in the UAE by Q2 2025. Future plans include extending the technology’s application to other cancers, such as pancreatic and lung cancer.
Broader Applications Beyond Cancer
MediChip’s versatility extends beyond oncology to include:
- Chronic Diseases: Leveraging opioids and hormones.
- Advanced Therapies: Supporting biological, cellular, and genetic treatments.
Biosapien aims to treat over 1 million patients by 2035, aligning with the UAE’s commitment to advanced healthcare initiatives and improving quality of life through cutting-edge technologies.
This expansion underscores Biosapien’s vision to redefine drug delivery and revolutionize patient care on a global scale.
العربية (Arabic) To read the article in Arabic, click here
